CN101816792A - 包含埃坡霉素的组合及其药学用途 - Google Patents

包含埃坡霉素的组合及其药学用途 Download PDF

Info

Publication number
CN101816792A
CN101816792A CN201010166742A CN201010166742A CN101816792A CN 101816792 A CN101816792 A CN 101816792A CN 201010166742 A CN201010166742 A CN 201010166742A CN 201010166742 A CN201010166742 A CN 201010166742A CN 101816792 A CN101816792 A CN 101816792A
Authority
CN
China
Prior art keywords
combination
inhibitor
hydrogen
alkyl group
low alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201010166742A
Other languages
English (en)
Chinese (zh)
Inventor
J·A·霍奈克
J·A·米勒
J·D·罗瑟梅尔
M·瓦特曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN101816792A publication Critical patent/CN101816792A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201010166742A 2002-06-10 2003-06-06 包含埃坡霉素的组合及其药学用途 Pending CN101816792A (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US38702502P 2002-06-10 2002-06-10
US60/387,025 2002-06-10
US40623902P 2002-08-27 2002-08-27
US40623802P 2002-08-27 2002-08-27
US60/406,239 2002-08-27
US60/406,238 2002-08-27
US43867703P 2003-01-08 2003-01-08
US43867603P 2003-01-08 2003-01-08
US60/438,676 2003-01-08
US60/438,677 2003-01-08

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN038134489A Division CN1658904A (zh) 2002-06-10 2003-06-06 包含埃坡霉素的组合及其药学用途

Publications (1)

Publication Number Publication Date
CN101816792A true CN101816792A (zh) 2010-09-01

Family

ID=29741146

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201010166742A Pending CN101816792A (zh) 2002-06-10 2003-06-06 包含埃坡霉素的组合及其药学用途
CN038134489A Pending CN1658904A (zh) 2002-06-10 2003-06-06 包含埃坡霉素的组合及其药学用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN038134489A Pending CN1658904A (zh) 2002-06-10 2003-06-06 包含埃坡霉素的组合及其药学用途

Country Status (16)

Country Link
US (2) US20050271669A1 (https=)
EP (2) EP1515750B1 (https=)
JP (1) JP2005535608A (https=)
CN (2) CN101816792A (https=)
AT (1) ATE476995T1 (https=)
AU (1) AU2003242646A1 (https=)
BR (1) BR0311714A (https=)
CA (1) CA2487147A1 (https=)
DE (1) DE60333754D1 (https=)
IL (1) IL165180A0 (https=)
MX (1) MXPA04012444A (https=)
NO (1) NO20050096L (https=)
PL (1) PL372070A1 (https=)
SG (1) SG162616A1 (https=)
WO (1) WO2003103712A1 (https=)
ZA (1) ZA200409137B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7381825B2 (en) 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
JO2596B1 (en) * 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1824831A2 (en) 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1896436A2 (en) 2005-05-11 2008-03-12 Takeda San Diego, Inc. Histone deacetylase inhibitors
EA200800321A1 (ru) 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы
CN101677977A (zh) * 2006-11-10 2010-03-24 欣达克斯制药公司 用于治疗癌症的ERα+配体和组蛋白脱乙酰化酶抑制剂组合
WO2009015203A1 (en) * 2007-07-23 2009-01-29 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
US20100267779A1 (en) * 2007-07-23 2010-10-21 Syndax Pharmaceuticals, Inc. Novel Compounds and Methods of Using Them
US20090149511A1 (en) * 2007-10-30 2009-06-11 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC and an mTOR Inhibitor
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
CA2725390C (en) * 2008-04-08 2014-09-23 Syndax Pharmaceuticals, Inc. Use of a hdac inhibitor and a her-2 inhibitor in the treatment of breast cancer
US20110300150A1 (en) 2010-05-18 2011-12-08 Scott Eliasof Compositions and methods for treatment of autoimmune and other disease
WO2018081556A1 (en) * 2016-10-28 2018-05-03 Acetylon Pharmaceuticals, Inc. Pharmaceutical combinations comprising a histone deacetylase inhibitor and epothilone and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
CA2273083C (en) * 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
TR200002299T2 (tr) * 1998-02-05 2000-11-21 Novartis Ag Epotilon kompozisyonları.
CA2322157C (en) * 1998-02-25 2012-05-29 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
WO2000000485A1 (de) * 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
HK1044946A1 (zh) * 1999-02-11 2002-11-08 舍林股份公司 依泊昔酮衍生物、其製備方法及藥物用途
DE19908760A1 (de) * 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
JP2004500388A (ja) * 2000-03-01 2004-01-08 スローン−ケッタリング　インスティトュート　フォア　キャンサー　リサーチ エポチロン、その中間体およびその類似体の合成
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
DE10020517A1 (de) * 2000-04-19 2001-10-25 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE10020899A1 (de) * 2000-04-20 2001-10-25 Schering Ag 9-Oxa-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
IL157443A0 (en) * 2001-03-14 2004-03-28 Bristol Myers Squibb Co Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent

Also Published As

Publication number Publication date
EP1515750B1 (en) 2010-08-11
ATE476995T1 (de) 2010-08-15
BR0311714A (pt) 2005-03-01
JP2005535608A (ja) 2005-11-24
MXPA04012444A (es) 2005-04-19
EP2179745A1 (en) 2010-04-28
NO20050096L (no) 2005-02-04
CA2487147A1 (en) 2003-12-18
IL165180A0 (en) 2005-12-18
AU2003242646A1 (en) 2003-12-22
WO2003103712A1 (en) 2003-12-18
EP1515750A1 (en) 2005-03-23
CN1658904A (zh) 2005-08-24
SG162616A1 (en) 2010-07-29
PL372070A1 (en) 2005-07-11
HK1075208A1 (en) 2005-12-09
US20050271669A1 (en) 2005-12-08
US20110033458A1 (en) 2011-02-10
DE60333754D1 (de) 2010-09-23
ZA200409137B (en) 2005-08-31

Similar Documents

Publication Publication Date Title
US20110033458A1 (en) Combinations comprising epothilones and pharmaceutical uses thereof
JP7221699B2 (ja) Ａｒ＋乳癌の治療方法
JP2023533447A (ja) がんを処置する併用療法
CN115845070A (zh) 用notch和pd-1或pd-l1抑制剂的组合治疗
EP3053578B1 (en) Combination cancer therapy using azabicyclo compound
TWI482621B (zh) 青蒿素基藥物與其他化學治療劑的抗癌組合物
JP2003533485A5 (https=)
KR20220143154A (ko) 네라티닙을 이용한 유방암의 치료법
TW201127384A (en) Therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent
CN111386113A (zh) 包含lsz102和阿培利司的药物组合
WO2006113304A2 (en) Combinations, methods and compositions for treating cancer
JP2021523190A (ja) 腺様嚢胞癌を治療するためのビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物を含む組成物
US9492469B2 (en) Combination therapy for the treatment of proliferative diseases
WO2004032925A1 (en) Use of imatinib (glivec, sti-571) to inhibit breast cancer resistance protein (bcrp)-mediated resistance to therapeutic agents
CN111315378A (zh) 包含lsz102和瑞博西尼的药物组合
RU2379032C9 (ru) Комбинации, включающие эпотилоны, и их фармацевтическое применение
EP1485090B1 (en) Combinations comprising an epothilone derivative and an imidazotetrazinone
CN1988904A (zh) 埃坡霉素组合
EP1951243B1 (en) Treatment of solid tumor diseases with combinations comprising imatinib and an efflux pump inhibitor
AU2008200068B2 (en) Combinations comprising epothilones and pharmaceutical uses thereof
KR20050019125A (ko) 에포틸론을 포함하는 조합물 및 그의 제약적 용도
NZ537040A (en) Treating a proliferative disease comprising administering to the animal a combination that comprises (a) a HER-1 or a HER-2 antibody or (b) at least one antineoplastic agent
HK1141234A (en) Combinations comprising epothilones and pharmaceutical uses thereof
US20030139430A1 (en) Use of organic compounds
CN103561745A (zh) 用于治疗癌症的药剂和方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20100901